SCHEMBL2030179

SCHEMBL2030179

NC(CC(=O)O)c1cccs1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.44
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
KEAP1 Q14145 1/20 0.43
CYP2C19 P33261 1/20 0.42
SLC1A3 P43003 1/20 0.41
SLC1A2 P43004 1/20 0.41
SLC1A1 P43005 1/20 0.41
ALDH1A1 P00352 4/20 0.40
RAB9A P51151 3/20 0.40
HPGD P15428 2/20 0.40
NPC1 O15118 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
DAO P14920 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3351265 1.00 ALOX5 (0.44) ALOX5CES2CES1KEAP1CYP2C19
SCHEMBL2481473 1.00 ALOX5 (0.44) ALOX5CES2CES1KEAP1CYP2C19
SCHEMBL5846678 0.91 RAB9A (0.41) ALOX5CES2CES1KEAP1SLC1A3
SCHEMBL5846668 0.91 RAB9A (0.41) ALOX5CES2CES1KEAP1SLC1A3
SCHEMBL11544964 0.84 HPGD (0.44) ALOX5CES2CES1KEAP1CYP2C19
SCHEMBL11413903 0.84 ALOX5 (0.42) ALOX5CES2CES1KEAP1CYP2C19
SCHEMBL658090 0.81 CES2 (0.46) ALOX5CES2CES1KEAP1CYP2C19
SCHEMBL28642254 0.81 CES2 (0.44) ALOX5CES2CES1KEAP1CYP2C19
SCHEMBL1143873 0.80 ALOX5 (0.43) ALOX5CES2CES1KEAP1CYP2C19
SCHEMBL1520244 0.80 ALOX5 (0.43) ALOX5CES2CES1KEAP1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110127869-B Environment-friendly neutral scale and corrosion inhibitor for oil extraction and preparation method thereof 黑龙江益瑞化工有限公司 2020-10-09 CN claimed
CN-110127869-A A kind of environment-friendly type oil recovery neutral anti-incrustation corrosion inhibitor and preparation method thereof 黑龙江益瑞化工有限公司 2019-08-16 CN claimed
US-7015348-B2 Method for producing an optically active β-amino acid TAKASAGO INTERNATIONAL CORPORATION (JP) 2006-03-21 US claimed
US-20250367300-A1 Nanomaterial and Methods of Use Thereof UNIVERSITY OF CONNECTICUT (US) 2025-12-04 US disclosed
US-20250302971-A1 Therapeutic Nanomaterials UNIV CONNECTICUT (US) 2025-10-02 US disclosed
US-20250229081-A1 NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF UNIVERSITY OF CONNECTICUT 2025-07-17 US disclosed
EP-4578868-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR FUJIFILM Corporation (JP) 2025-07-02 EP disclosed
EP-4578867-A1 CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR FUJIFILM Corporation (JP) 2025-07-02 EP disclosed
CN-120202010-A Ligand-oligonucleotide conjugates and linkers for use therewith 上海京新生物医药有限公司 2025-06-24 CN disclosed
WO-2025124377-A1 SOLAR CELL, INTERFACE PASSIVATION MATERIAL, PHOTOVOLTAIC POWER GENERATION SYSTEM AND ELECTRIC DEVICE 宁德时代未来能源(上海)研究院有限公司 2025-06-19 WO disclosed
US-20250179119-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR FUJIFILM CORPORATION (JP) 2025-06-05 US disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed
EP-0528997-B1 DISULFIDE DERIVATIVES OF MERCAPTOACYLAMINO ACIDS SCHERING CORP (US) 1995-02-01 EP disclosed
US-5219886-A Cardiovascular disorders, analgesics, enzyme inhibitors SCHERING CORPORATION (US) 1993-06-15 US disclosed
EP-0393441-B1 MERCAPTO-ACYLAMINO ACIDS SCHERING CORPORATION (US) 1993-05-26 EP disclosed
EP-0528997-A1 DISULFIDE DERIVATIVES OF MERCAPTOACYLAMINO ACIDS. SCHERING CORP (US) 1993-03-03 EP disclosed
EP-0467957-A1 MERCAPTO-ACYLAMINO ACIDS SCHERING CORPORATION (US) 1992-01-29 EP disclosed
WO-1991017980-A1 DISULFIDE DERIVATIVES OF MERCAPTOACYLAMINO ACIDS SCHERING CORPORATION (US) 1991-11-28 WO disclosed
EP-0393441-A1 Mercapto-acylamino acids SCHERING CORPORATION (US) 1990-10-24 EP disclosed
WO-1990012003-A1 MERCAPTO-ACYLAMINO ACIDS SCHERING CORPORATION (US) 1990-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302971-A1 Therapeutic Nanomaterials TIE1, TEKT1, POLRMT ALOX5 4880/4885CES2 4115/4885CES1 4367/4885
US-20250179119-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR MLX, BMX, ADM2 ALOX5 4781/4885CES2 4824/4885CES1 4587/4885
US-20250367300-A1 Nanomaterial and Methods of Use Thereof EPCAM, CD47, JAK2 ALOX5 2288/4885CES2 3053/4885CES1 4465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.